Bench-to-bedside review: The role of C1-esterase inhibitor in sepsis and other critical illnesses

Critical Care

Volumn 15, Issue 1, 2010, Pages

  Singer, Mervyn ^a   Jones, Annie M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MSC Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; INOTROPIC AGENT;

ACUTE PANCREATITIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CRITICALLY ILL PATIENT; DRUG MECHANISM; HEART PROTECTION; HUMAN; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPSIS; SEPTIC SHOCK; THERMAL INJURY; XENOTRANSPLANTATION;

EID: 84856608749     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9304     Document Type: Review

References (67)

1. Rambach G, Wurzner R, Speth C. Complement: an efficient sword of innate immunity. Contrib Microbiol 2008, 15:78-100.
2. McPhaden AR, Whaley K. The complement system in sepsis and trauma. Br Med Bull 1985, 41:281-286.
3. Stoner HB. Interpretation of the metabolic effects of trauma and sepsis. J Clin Pathol 1987, 40:1108-1117. 1141178, 3312301.
4. Ward PA. Sepsis, apoptosis and complement. Biochem Pharmacol 2008, 76:1383-1388. 2656915, 18848819.
5. Ward PA, Gao H. Sepsis, complement, and the dysregulated inflammatory response. J Cell Mol Med 2009, 13:4154-4160.
6. Ward PA. Role of the complement in experimental sepsis. J Leukoc Biol 2008, 83:467-470.
7. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787. 2786961, 18802444.
8. Davis AE, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol 2008, 45:4057-4063. 2626406, 18674818.
9. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 2007, 62:842-856.
10. Cai S, Dole VS, Bergmeier W, Scafidi J, Feng H, Wagner DD, Davis AE. A direct role for C1 inhibitor in regulation of leukocyte adhesion. Immunol 2005, 174:6462-6466.
11. Beinrohr L, Harmat V, Dobo J, Lorincz Z, Gal P, Zavodszky P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007, 282:21100-21109.
12. Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962, 33:330-341.
13. Albrecht EA, Ward PA. Complement-induced impairment of the innate immune system during sepsis. Curr Infect Dis Rep 2005, 7:349-354.
14. Monefeldt K, Helgeland K, Tollefsen T. In vitro activation of the classical pathway of complement by a streptococcal lipoteichoic acid. Oral Microbiol Immunol 1994, 9:70-76.
15. Flierl MA, Rittirsch D, Nadeau BA, Day DE, Zetoune FS, Sarma JV, Huber-Lang MS, Ward PA. Functions of the complement components C3 and C5 during sepsis. FASEB J 2008, 22:3483-3490. 2537435, 18587006.
16. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, Zetoune FS, Gerard NP, Cianfl one K, Köhl J, Gerard C, Sarma JV, Ward PA. Functional roles for C5a receptors in sepsis. Nat Med 2008, 14:551-557. 2753858, 18454156.
17. Niederbichler AD, Hoesel LM, Westfall MV, Gao H, Ipaktchi KR, Sun L, Zetoune FS, Su GL, Arbabi S, Sarma JV, Wang SC, Hemmila MR, Ward PA. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J Exp Med 2006, 203:53-61. 2118072, 16380509.
18. Croner RS, Lehmann TG, Fallsehr C, Herfarth C, Klar E, Kirschfink M. C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat. Microvasc Res 2004, 67:182-191.
19. Schmidt W, Stenzel K, Walther A, Gebhard MM, Martin E, Schmidt H. Influence of C1-esterase inhibitor on tissue oxygenation of jejunal mucosa during endotoxemia. Int J Surg Investig 1999, 1:277-283.
20. Lehmann C, Birnbaum J, Lührs C, Rückbeil O, Spies C, Ziemer S, Gründling M, Pavlovic D, Usichenko T, Wendt M, Kox WJ. Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia. Intensive Care Med 2004, 30:309-314.
21. Fischer MB, Prodeus AP, Nicholson-Weller A, Ma M, Murrow J, Reid RR, Warren HB, Lage AL, Moore FD, Rosen FS, Carroll MC. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 1997, 159:976-982.
22. Giebler R, Schmidt U, Koch S, Peters J, Scherer R. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin. Crit Care Med 1999, 27:597-604.
23. Guerrero R, Velasco F, Rodriguez M, Lopez A, Rojas R, Alvarez MA, Villalba R, Rubio V, Torres A, del Castillo D. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. J Clin Invest 1993, 91:2754-2760. 443341, 8514883.
24. Jansen PM, Eisele B, de Jong IW, Chang A, Delvos U, Taylor FB, Hack CE. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998, 160:475-484.
25. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis AE. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003, 171:2594-2601.
26. Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE. C1 inhibitor-mediated protection from sepsis. J Immunol 2007, 179:3966-3972.
27. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995, 91:393-402.
28. Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 1998, 286:429-438.
29. Horstick G, Heimann A, Götze O, Hafner G, Berg O, Böhmer P, Becker P, Darius H, Rupprecht HJ, Loos M, Bhakdi S, Meyer J, Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997, 95:701-708.
30. Horstick G, Berg O, Heimann A, Götze O, Loos M, Hafner G, Bierbach B, Petersen S, Bhakdi S, Darius H, Horstick M, Meyer J, Kempski O. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: doserelated beneficial versus detrimental effects. Circulation 2001, 104:3125-3131.
31. Fu J, Lin G, Wu Z, Ceng B, Wu Y, Liang G, Qin G, Li J, Chiu I, Liu D. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochem Biophys Res Commun 2006, 349:504-512.
32. Fu J, Lin G, Zeng B, Wu Z, Wu Y, Chu H, Qin G, Liang G, Li J, Gan X, Yu X, Li C, Liu D. Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity. Biochem Biophys Res Commun 2006, 350:162-168.
33. Lu F, Chauhan AK, Fernandes SM, Walsh MT, Wagner DD, Davis AE. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2008, 295:G1042-1049.
34. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 2008, 371:143-152.
35. Niederau C, Brinsa R, Niederau M, Luthen R, Strohmeyer G, Ferrell LD. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol 1995, 17:189-196.
36. Bhatia M, Saluja AK, Singh VP, Frossard JL, Lee HS, Bhagat L, Gerard C, Steer ML. Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 2001, 280:G974-978.
37. Tomasdottir H, Henriksson BA, Bengtson JP, Bengtsson A, Stenqvist O, Persson H. Complement activation during liver transplantation. Transplantation 1993, 55:799-802.
38. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993, 56:1171-1176.
39. Fiane AE, Videm V, Johansen HT, Mellbye OJ, Nielsen EW, Mollnes TE. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology 1999, 42:231-243.
40. Pöling J, Oezkur M, Kogge K, Mengel M, Niemann H, Winkler M, Haverich A, Wiebe K. Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins. Transpl Int 2006, 19:225-232.
41. Schelzig H, Simon F, Krischer C, Vogel A, Abendroth D. Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor. Ann Transplant 2001, 6:34-39.
42. Schröder C, Pfeiffer S, Wu G, Zorn GL, Ding L, Allen C, Harrison RA, White DJ, Azimzadeh AM, Pierson RN. Effect of complement fragment 1 esterase inhibition on survival of human decay-accelerating factor pig lungs perfused with human blood. J Heart Lung Transplant 2003, 22:1365-1375.
43. Hecker JM, Lorenz R, Appiah R, Vangerow B, Loss M, Kunz R, Schmidtko J, Mengel M, Klempnauer J, Piepenbrock S, Dickneite G, Neidhardt H, Rückoldt H, Winkler M. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation 2002, 73:688-694.
44. Hecker JM, Loss M, Klempnauer J, Winkler M. C1-inhibitor for therapy and prophylaxis of acute vascular rejection of porcine kidneys in cynomolgus monkeys. Transplant Proc 2002, 34:2382.
45. Radke A, Mottaghy K, Goldmann C, Khorram-Sefat R, Kovacs B, Janssen A, Klosterhalfen B, Hafemann B, Pallua N, Kirschfi nk M. C1 inhibitor prevents capillary leakage after thermal trauma. Crit Care Med 2000, 28:3224-3232.
46. Zwahlen A, Nydegger UE, Vaudaux P, Lambert PH, Waldvogel FA. Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis. J Infect Dis 1982, 145:635-646.
47. Zwijnenburg PJ, van der Poll T, Florquin S, Polfliet MM, van den Berg TK, Dijkstra CD, Roord JJ, Hack CE, van Furth AM. C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. J Infect Dis 2007, 196:115-123.
48. Charneski L, Patel PN. Eculizumab in paroxysmal nocturnal haemoglobinuria. Drugs 2008, 68:1341-1346.
49. Hack CE, Voerman HJ, Eisele B, Keinecke HO, Nuijens JH, Eerenberg AJ, Ogilvie A, Strack van Schijndel RJ, Delvos U, Thijs LG. C1-esterase inhibitor substitution in sepsis. Lancet 1992, 339:378.
50. Hack CE, Ogilvie AC, Eisele B, Jansen PM, Wagstaff J, Thijs LG. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994, 388:335-357.
51. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen HU, Zürcher-Zenklusen R, Rieben R, Devay J, Hack CE, Lämmle B, Wuillemin WA. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002, 30:1722-1728.
52. Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Sulzer I, Hack CE, Wuillemin WA. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003, 10:529-535. 164269, 12853381.
53. Lazareva NB, Igonin AA. [Safety and efficacy of purified human C1-esterase inhibitor in the treatment of patients with sepsis]. Antibiot Khimioter 2009, 54:42-46.
54. Tapisiz A, Ergenekon E, Oktem M, Koc E, Okumus N, Zenciroǧlu A, Atalay Y. C1 inhibitor level on neonatal sepsis and its relations with clinical findings. Paediatr Child Health 2010, 46:121-124.
55. Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 1998, 24:635-638.
56. de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002, 23:1670-1677.
57. Thielmann M, Marggraf G, Neuhäuser M, Forkel J, Herold U, Kamler M, Massoudy P, Jakob H. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg 2006, 30:285-293.
58. Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, Guccione F, Dioguardi P, Ruvolo G. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 2007, 32:326-332.
59. Nurnberger W, Heying R, Burdach S, Gobel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol 1997, 75:95-101.
60. Strüber M, Hagl C, Hirt SW, Cremer J, Harringer W, Haverich A. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med 1999, 25:1315-1318.
61. Kowal-Vern A, Walenga JM, Sharp-Pucci M, Hoppensteadt D, Gamelli RL. Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor. J Burn Care Rehabil 1997, 18:99-103.
62. Davis AE, Cai S, Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology 2007, 212:313-323. 2680681, 17544816.
63. Guo RF, Ward PA. C5a, a therapeutic target in sepsis. Recent Pat Antiinfect Drug Discov 2006, 1:57-65.
64. Drug Commission of the German Medical Profession: Serious Thrombogenesis Following Berinert HS. Dtsch Arztebl 2000, 97. A-1016/B-864/C-812.
65. Temiño VM, Peebles RS. The spectrum and treatment of angioedema. Am J Med 2008, 121:282-286.
66. Lou J, Lucas R, Grau GE. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin Microbiol Rev 2001, 14:810-820. 89004, 11585786.
67. Levinson WE. Review of Medical Microbiology and Immunology 2006, New York: McGraw-Hill Medical, 9.